Clinical Trials Logo

Clinical Trial Summary

The purpose of this observational study is to collect real-world data that describes treatment patterns and clinical outcomes in participants with first line recurrent/metastatic squamous cell carcinoma of the head & neck (1L R/M SCCHN).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05123950
Study type Observational
Source Bristol-Myers Squibb
Contact
Status Completed
Phase
Start date January 1, 2019
Completion date March 19, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT04659369 - Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT02572778 - Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Terminated NCT01488318 - Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT00999700 - Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Phase 3
Completed NCT02565758 - ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02543476 - SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) N/A
Recruiting NCT03938012 - Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
Terminated NCT02124850 - A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab Phase 1
Recruiting NCT03313804 - Priming Immunotherapy in Advanced Disease With Radiation Phase 2
Recruiting NCT04453046 - Hemopurifier Plus Pembrolizumab in Head and Neck Cancer N/A
Completed NCT01758731 - Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History Phase 1
Completed NCT02473731 - A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Phase 1
Active, not recruiting NCT02022098 - Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial N/A
Completed NCT01458392 - Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2
Completed NCT02882308 - Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. Phase 2
Recruiting NCT04590963 - Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer Phase 3
Recruiting NCT03646461 - Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC Phase 2